History Spacebook: A Constructive Use of Wikis in Social Studies

This study examines student engagement and short-term and long-term achievement when a wiki was used constructively in place of traditional lecture to learn about the Civil Rights Movement. The study was conducted with students enrolled in two rural high school contemporary issues classes in the southeastern United States. The results indicated that participants in the experimental and control groups were engaged and enjoyed the topic that was studied. The participants in the experimental group showed significant increases in engagement while synthesizing information from numerous resources to develop wiki pages and while working collaboratively with other participants. There was no significant increase in short-term or long-term student achievement. Students in both groups enjoyed learning about the Civil Rights Movement, but several became emotional, voicing concerns. Comments included, “I hate the thought [of] that happening to people, and I couldn’t imagine going through that or watching others go through it. It was cruel and wrong and I don’t understand how people can hate someone on the basis of their skin.” Another added, “it [Civil Rights Movement] is still a touchy subject,” and yet another said, “the Civil Rights Movement was a beautiful display of courage, support, and righteousness.

Operationally defining sexual orientation : towards the development of a fundamental measure of adolescent sexual responsiveness variations

Much published work has pointed to the need for the development of a sound operational definition of sexual orientation in order to enable the research in this area to progress. To contribute to this process the current research set out to develop two measures of sexual orientation and examine their psychometric properties. In order to develop relevant tools historical, conceptual and operational definitions of sexual orientation were critically examined and standard questionnaire development techniques applied. The first scale consisted of 32 items and was administered to a total of 835 adolescents, comprising three sub-groups (189 Grade 11 Scholars, 547 First Year and 99 Third Year Psychology Students). A Cronbach alpha coefficient of 0.85 was calculated indicating that this instrument had very good internal consistency reliability. Similar factors emerged in each of the sample sub-groups when factor analyses were performed suggesting that this instrument has good external and construct validities. These factors each had respectable Cronbach alpha coefficients indicating their own internal consistency. The four factors which consistently emerged were Same Sex Responsiveness, Opposite Sex Responsiveness, Previous Month’s Same Sex Responsiveness and Previous Month’s Opposite Sex Responsiveness. The second scale consisted of 16 items and was administered to 646 adolescents, comprising the latter two sub-groups referred to above. A Cronbach alpha coefficient of 0.82 was calculated indicating that this instrument also had very good internal consistency reliability. Once again similar factors with generally good internal consistency emerged in factor analysis suggesting that this too was a valid instrument. The factors that emerged from the second scale were Same Sex Responsiveness, Unattractive Opposite Sex Responsiveness, Attractive Opposite Sex Responsiveness and Attraction. Future developments, adjustments and applications of the instruments as well as implications for the arena of sexual orientation research are discussed. In the light of the dearth of information with regard to the sexual orientations of South African adolescents the current study also briefly explored and presented the sample’s responses in terms of the dimensions of each questionnaire as well as how each emerging factor related to the demographics (education level, gender, sexual orientation self-label and age) of the sample

The development of a scale to measure sexual orientation and an examination of its psychometric properties

The purpose of the study was to develop a scale to measure sexual orientation and to examine its psychometric properties. Previous scales were critically examined and compared and the need for a scale which simultaneously measures same and opposite sex responsiveness independently, and accounts for dynamic changes over time, while testing a number of overt and covert dimensions of sexual orientations, was established. A 48-item scale was designed to tap self-reported intensity and frequency of Emotional Attachment, Sexual Fantasy, Sexual Attraction and Sexual Contact towards males and females in the Past, Present and Future. An initial study was conducted with 13 undergraduate university students of both genders, representing a variety of sexual orientations and nationalities, and qualitative feedback was obtained and utilized to make appropriate adjustments and refinements to the scale. The scale was then administered to 133 Rhodes University undergraduate psychology students to obtain quantitative data with regard to its internal structure. The scale was found to have a good internal consistency reliability Cronbach alpha coefficient of 0.8106. Existing sub-scales had lower alpha coefficients. Factor analysis, a form of construct validation, was performed and four factors emerged. These had very good internal consistency reliability alpha coefficients: Sexual Responsiveness to Females (0.9894), Sexual Responsiveness to Males (0.9741), Emotional Attachment to Females (0.8403) and Emotional Attachment to Males (0.8372). These factors were further statistically analysed to ascertain how they relate to one another and to the demographics of gender, age, relational status and sexual orientation identity. Future research will need to assess other forms of reliability and validity and focus on larger and more varied samples

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer

Introduction/Background. Nonmetastatic castrate resistant prostate cancer (CRPC) is a challenging disease state. The objective of this study was to evaluate the efficacy and tolerability of bevacizumab in nonmetastatic CRPC patients. Patients. Patients with prostate cancer who developed PSA recurrence after local therapy were included if they had absence of bone or visceral metastases and PSA progression despite androgen deprivation therapy. Methods. Bevacizumab 10 mg/kg intravenously was administered every 14 days until PSA progression, development of metastasis, or unacceptable toxicity. Results. 15 patients were enrolled and treated with bevacizumab for a median duration of 3.1 months. Median baseline PSA was 27 ng/mL, and seven patients had Gleason Score ≥8. Five patients had declined in PSA during the treatment. Median PSA doubling time was prolonged from 4.7 months pretreatment to 6.5 months. Median time to PSA progression and new metastasis were 2.8 and 7.9 months, respectively. There were three grade 3 adverse events (one proteinuria and two hypertension) and one pulmonary embolism. There was no treatment-related mortality. Conclusion. Bevacizumab therapy had minimal impact on the disease course of nonmetastatic CRPC, and investigation of novel strategies is needed

Climate in Asia and the Pacific: A Synthesis of APN Activities

The synthesis report is part of the APN’s larger aim to contribute, from the science perspective, to the development of policy options for appropriate responses to climate vulnerability and impacts, including adaptation and mitigation, which in turn will contribute to sustainable development

Anti-androgenic activity of absorption-enhanced 3, 3\u27-diindolylmethane in prostatectomy patients

Consumption of cruciferous vegetables is associated with a decreased risk of developing prostate cancer. Antineoplastic effects of cruciferous vegetables are attributable to bioactive indoles, most prominently, 3, 3\u27-diindolylmethane (DIM). In addition to effects on proliferation and apoptosis, DIM acts as an antiandrogen in prostate cancer cell lines. This study characterized the effects of prostatic DIM on the androgen receptor (AR) in patients with prostate cancer. Men with localized prostate cancer were treated with a specially formulated DIM capsule designed for enhanced bioavailability (BR-DIM) at a dose of 225 mg orally twice daily for a minimum of 14 days. DIM levels and AR activity were assessed at the time of prostatectomy. Out of 28 evaluable patients, 26 (93%) had detectable prostatic DIM levels, with a mean concentration of 14.2 ng/gm. The mean DIM plasma level on BR-DIM therapy was 9.0 ng/mL; levels were undetectable at baseline and in follow-up samples. AR localization in the prostate was assessed with immunohistochemistry. After BR-DIM therapy, 96% of patients exhibited exclusion of the AR from the cell nucleus. In contrast, in prostate biopsy samples obtained prior to BR-DIM therapy, no patient exhibited AR nuclear exclusion. Declines in PSA were observed in a majority of patients (71%). Compliance was excellent and toxicity was minimal. In summary, BR-DIM treatment resulted in reliable prostatic DIM levels and anti-androgenic biologic effects at well tolerated doses. These results support further investigation of BR-DIM as a chemopreventive and therapeutic agent in prostate cancer

Closing The Brief Case: A Rare Case of Invasive Amebiasis Requiring Emergency Subtotal Colectomy in an HIV-Positive Man.

In April 2017, a 56-year-old HIV-positive man was transferred from another institution to our regional infectious disease unit having presented with 2 weeks of profuse, watery diarrhea accompanied by intermittent, fresh bleeding of the rectum. Symptoms had started during a 2-month vacation to Indonesia, Vietnam, and Malaysia. While on vacation, he stayed in hotels in urban areas, had no rural travel, and drank only bottled water. He reported that he was not a man who has sex with men (MSM) and preferred to discuss his further sexual history confidentially with the genitourinary medicine team. Two months prior to admission, his CD4 count was 194 cells/mm3, and while taking an antiretroviral therapy regimen consisting of tenofovir, emtricitabine, and nevirapine, his HIV RNA had been undetectable in his plasma for 3 years

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial

Importance: Black patients have been underrepresented in prospective clinical trials of advanced prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer (mHSPC), which is a disease state responsive to androgen deprivation therapy (ADT). Objective: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients. Design, Setting, and Participants: In this randomized clinical trial, a phase 2 screening design enabled a nondefinitive comparison of the primary outcome by treatment. Patients were stratified by race (Black or other) and bone pain (present or absent). Accrual of at least 30% Black patients was required. This multicenter trial was conducted at 4 centers in the US. Men with mHSPC with no history of seizures and adequate marrow, renal, and liver function were eligible. Data analysis was performed from February 2019 to March 2020. Interventions: Participants were randomized 1:1 to receive oral enzalutamide (160 mg daily) or bicalutamide (50 mg daily) in addition to ADT. Main Outcomes and Measures: The primary end point was the 7-month prostate-specific antigen (PSA) response (SMPR) rate, a previously accepted surrogate for overall survival (OS) outcome. Secondary end points included adverse reactions, time to PSA progression, and OS. Results: A total of 71 men (median [range] age, 65 [51-86] years) were enrolled; 29 (41%) were Black, 41 (58%) were White, and 1 (1%) was Asian. Thirty-six patients were randomized to receive enzalutamide, and 35 were randomized to receive bicalutamide. Twenty-six patients (37%) had bone pain and 37 patients (52%) had extensive disease. SMPR was achieved in 30 of 32 patients (94%; 95% CI, 80%-98%) taking enzalutamide and 17 of 26 patients (65%; 95% CI, 46%-81%) taking bicalutamide (P = .008) (difference, 29%; 95% CI, 5%-50%). Among Black patients, the SMPR was 93% (95% CI, 69%-99%) among those taking enzalutamide and 42% (95% CI, 19%-68%) among those taking bicalutamide (P = .009); among non-Black patients, the SMPR was 94% (95% CI, 74%-99%) among those taking enzalutamide and 86% (95% CI, 60%-96%) among those taking bicalutamide. The 12-month PSA response rates were 84% with enzalutamide and 34% with bicalutamide. Conclusions and Relevance: The findings of this randomized clinical trial comparing enzalutamide with bicalutamide suggest that enzalutamide is associated with improved outcomes compared with bicalutamide, in terms of the rate and duration of PSA response, in Black patients with mHSPC. Trial Registration: ClinicalTrials.gov Identifier: NCT02058706